Vivacelle Bio

Executive Summary

Vivacelle Bio is a private biopharmaceutical company headquartered in Chicago, focused on developing transformative treatments for sepsis, a leading cause of death worldwide responsible for 11 million annual fatalities, including 3.4 million children. Founded in 2015, the company addresses a profound unmet medical need with its small molecule platform. While specific pipeline details are not publicly disclosed, Vivacelle Bio's mission targets a massive global market with high clinical urgency. The company remains in early stages with no disclosed funding rounds or valuation, indicating a need for capital to advance its programs. Its success hinges on demonstrating preclinical proof-of-concept and securing partnerships or grants to move toward clinical trials.

Upcoming Catalysts (preview)

• 2026Series A or Seed Funding Announcement60% success
• Q4 2026Preclinical Data Release for Lead Sepsis Candidate50% success
• 2027Research Collaboration or Licensing Deal40% success